tiprankstipranks
Amneal Pharmaceuticals Inc (AMRX)
NYSE:AMRX

Amneal Pharmaceuticals Stock Price & Analysis

315 Followers

AMRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.00 - $5.99
Previous Close$2.1
Volume1.02M
Average Volume (3M)1.08M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$91.98M
Total Debt (Recent Filing)$2.81B
P/E Ratio-2.4
Beta1.15
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.89
Shares Outstanding151,408,535
R-Squared0.17
Standard Deviation0.16
10 Day Avg. Volume1,151,395
30 Day Avg. Volume1,082,713
P/B Ratio-0.20
P/S Ratio0.15
P/CF Ratio2.20
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside90.48% Upside
Rating ConsensusModerate Buy
Alpha-0.04
Number of Analyst Covering1


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

AMRX FAQ

What was Amneal Pharmaceuticals’s price range in the past 12 months?
Amneal Pharmaceuticals lowest stock price was $2.00 and its highest was $5.99 in the past 12 months.
    What is Amneal Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Amneal Pharmaceuticals’s upcoming earnings report date?
    Amneal Pharmaceuticals’s upcoming earnings report date is Nov 09, 2022 which is in 45 days.
      How were Amneal Pharmaceuticals’s earnings last quarter?
      Amneal Pharmaceuticals released its earnings results on Aug 05, 2022. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.194 by -$0.004.
        Is Amneal Pharmaceuticals overvalued?
        According to Wall Street analysts Amneal Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Amneal Pharmaceuticals pay dividends?
          Amneal Pharmaceuticals does not currently pay dividends.
          What is Amneal Pharmaceuticals’s EPS estimate?
          Amneal Pharmaceuticals’s EPS estimate is $0.18.
            How many shares outstanding does Amneal Pharmaceuticals have?
            Amneal Pharmaceuticals has 151,408,540 shares outstanding.
              What happened to Amneal Pharmaceuticals’s price movement after its last earnings report?
              Amneal Pharmaceuticals reported an EPS of $0.19 in its last earnings report, missing expectations of $0.194. Following the earnings report the stock price went down -8.092%.
                Which hedge fund is a major shareholder of Amneal Pharmaceuticals?
                Among the largest hedge funds holding Amneal Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Amneal Pharmaceuticals’s shares valued at 572K.

                  ---

                  Amneal Pharmaceuticals Stock Analysis

                  Smart ScoreUnderperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  1
                  The Amneal Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Amneal Pharmaceuticals Inc

                  Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Johnson & Johnson
                  Eli Lilly & Co
                  Pfizer
                  Merck & Company
                  Bristol Myers

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis